Fortis Healthcare Ltd. (FORTIS) AI Stock Analysis

• Market Cap: ₹769.00B
• Dividend Yield: 0.1%
• Average Volume (3M): 66.29K
• Price to Earnings (P/E): 88.5
• Beta (1Y): 1.05
• Revenue Growth: 14.04%
• EPS Growth: 32.99%
• Country: IN
• Employees: 12,088
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 3.40
• Shares Outstanding: 754,958,100
• 10 Day Avg. Volume: 118,360
• 30 Day Avg. Volume: 66,292
• PEG Ratio: 2.28
• Price to Book (P/B): 5.83
• Price to Sales (P/S): 6.67
• P/FCF Ratio: 90.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹970.00
• Price Target Upside: -4.93% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ₹1,175.00 ▲(15.16% Upside)

Fortis Healthcare Ltd. has a strong financial foundation with consistent revenue growth and improved profitability, which is the most significant factor in its score. However, the technical analysis indicates potential overbought conditions, and the high P/E ratio suggests overvaluation, which tempers the overall score.

Fortis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Fortis Healthcare Limited, an integrated healthcare delivery service provider, offers secondary, tertiary, and quaternary care in India, the United Arab Emirates, Sri Lanka, and internationally. Its healthcare verticals comprise hospitals, diagnostics, and day care specialty facilities. The company offers services in the areas of cardiac science, cosmetology, dental science, dermatology, diabetes/endocrinology, emergency medicine, ENT, foetal medicine, gastroenterology and hepatology science, general surgery, haematology, infertility medicine, internal medicine, mental health and behavioral science, nephrology, neuro surgery, neurointerventional radiology, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy and rehabilitation, plastic and reconstructive surgery, pulmonology, radiology, rheumatology, thoracic surgery, transplantation medicine, urology, and other support specialties. As of March 31, 2022, it operated a network of 26 hospitals with approximately 4,300 operational beds. The company also operates approximately 426 diagnostics centers and laboratories; and 2,550 collection centers. The company was incorporated in 1996 and is based in Gurugram, India.

How the Company Makes Money

Fortis Healthcare generates revenue primarily through its hospital operations, which include inpatient and outpatient services. The company charges patients for medical treatments, surgeries, and diagnostic services. Additionally, it earns revenue from its diagnostic centers by providing laboratory and imaging services. Fortis has also established partnerships with insurance companies to facilitate cashless treatment options for insured patients, which contributes to a steady stream of income. Furthermore, the company may engage in strategic collaborations and alliances with healthcare providers and technology companies to enhance service delivery and expand its market reach, thereby positively impacting its earnings.

Fortis Healthcare Ltd. Financial Statement Overview

Summary

Fortis Healthcare Ltd. shows strong financial performance with consistent revenue growth and improved profitability. The income statement is robust, with high gross profit margins and positive net profit margins. The balance sheet reflects financial stability with an improving debt-to-equity ratio, though total debt levels need monitoring. Cash flow management is effective, supporting expansion and operational needs.

Income Statement

Fortis Healthcare Ltd. has demonstrated a strong income statement performance with consistent revenue growth, particularly from 2021 to 2025. The gross profit margin has remained robust, averaging above 40% in recent years, indicating effective cost management. Net profit margins have improved significantly, turning from negative to positive, showcasing enhanced profitability. EBIT and EBITDA margins have also seen notable improvements, indicating operational efficiency gains.

Balance Sheet

The company's balance sheet is solid with a healthy equity ratio, reflecting financial stability. The debt-to-equity ratio has been improving, suggesting prudent financial management and reduced leverage risk. Return on equity has increased, highlighting better efficiency in generating profits from shareholders' equity. However, the total debt level remains a consideration, though manageable given the company's growth trajectory.

Cash Flow

Fortis Healthcare Ltd. exhibits a positive cash flow trajectory, with significant growth in free cash flow over the years. The operating cash flow to net income ratio indicates strong cash-generating ability relative to accounting profits. However, fluctuations in capital expenditures and investing cash flows highlight potential volatility in future cash flows. Overall, cash flow management appears effective, supporting the company's expansion and operational needs.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	77.83B	77.86B	68.97B	62.98B	57.18B	40.30B
Gross Profit	30.52B	45.86B	39.73B	23.08B	32.25B	20.72B
EBITDA	14.98B	15.00B	11.87B	10.37B	9.96B	3.47B
Net Income	7.74B	7.74B	5.99B	5.89B	5.55B	-1.10B
Balance Sheet
Total Assets	136.92B	136.92B	132.89B	124.34B	118.85B	111.55B
Cash, Cash Equivalents and Short-Term Investments	5.08B	5.08B	6.00B	3.66B	4.13B	4.16B
Total Debt	24.75B	24.75B	11.55B	9.26B	12.55B	15.31B
Total Liabilities	45.22B	45.22B	47.33B	43.33B	48.76B	44.37B
Stockholders Equity	89.17B	89.17B	76.63B	72.42B	61.78B	61.20B
Cash Flow
Free Cash Flow	0.00	5.77B	1.58B	3.75B	6.50B	2.67B
Operating Cash Flow	0.00	14.24B	11.00B	8.22B	8.65B	4.85B
Investing Cash Flow	0.00	-7.79B	-8.86B	-3.74B	-5.14B	-1.35B
Financing Cash Flow	0.00	-7.14B	-864.58M	-4.71B	-5.17B	-1.43B

Fortis Healthcare Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1020.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FORTIS, the sentiment is Neutral. The current price of 1020.35 is below the 20-day moving average (MA) of 1058.38, above the 50-day MA of 1001.54, and above the 200-day MA of 788.35, indicating a neutral trend. The MACD of 4.12 indicates Positive momentum. The RSI at 46.89 is Neutral, neither overbought nor oversold. The STOCH value of 21.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:FORTIS.

Fortis Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NH	70 Outperform	₹372.01B	47.14	―	0.25%	12.09%	-2.79%
APOLLOHOSP	66 Neutral	₹1.12T	71.40	―	0.24%	13.66%	41.32%
LALPATHLAB	66 Neutral	₹264.07B	49.19	―	0.81%	10.80%	32.79%
FORTIS	64 Neutral	₹769.00B	88.54	―	0.10%	14.04%	32.99%
METROPOLIS	61 Neutral	₹105.27B	68.82	―	―	15.41%	5.93%
MANKIND	59 Neutral	₹977.97B	50.87	―	0.04%	23.22%	-19.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Fortis Healthcare Ltd. Corporate Events

Fortis Healthcare Completes Postal Ballot Notice Transmission

Fortis Healthcare Limited announced the publication of newspaper advertisements regarding the completion of electronic transmission of a Postal Ballot Notice to its members. This announcement is part of the company’s compliance with SEBI regulations, ensuring transparency and communication with its stakeholders.

Fortis Healthcare Reports Debt Securities Details

Fortis Healthcare Limited has reported details of its debt securities issued through private placement as per the SEBI Master Circular. The company has listed debt securities with an issuance date of December 19, 2024, and a maturity date of December 19, 2029, with an initial coupon rate of 8.486% per annum. This announcement is part of their compliance with regulatory requirements and reflects the company’s ongoing financial management strategy.

Fortis Healthcare Executes Tripartite Agreement for Greater Noida Facility

Fortis Healthcare Limited announced the execution of a tripartite agreement involving its wholly owned subsidiary, International Hospital Limited (IHL), Uttar Pradesh Industrial Development Authority (UPSIDA), and R.R. Lifesciences Pvt Ltd. This agreement pertains to the sub-leasing of hospital land, building, and equipment in Greater Noida, which is expected to enhance Fortis Healthcare’s operational capabilities and strengthen its market position.

Fortis Healthcare Expands Operations with New Tripartite Agreement

Fortis Healthcare Limited has announced the execution of a tripartite agreement involving the Uttar Pradesh Industrial Development Authority, R.R. Lifesciences Pvt Ltd, and International Hospital Limited, a wholly-owned subsidiary of Fortis. This agreement pertains to the sub-leasing of hospital land, building, and equipment in Greater Noida to International Hospital Limited, which could enhance Fortis’s operational capacity and strengthen its position in the healthcare sector.